*Dutch Marines study on Rabies antibody response after Boostering an intradermal pre-exposure scheme (MaRaBoo study)*

Completed

• Conditions: Rabies; 10047438

• Registration Number: NL-OMON45312
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Trial ended prematurely

Detailed Description

Not available

Study Timeline

• Study Completion: 2019-02-04
• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 24

Inclusion Criteria

Healthy military volunteers that received a completed intradermal immunization last year or 2 years ago.

Exclusion Criteria

- Age < 18 years;
- No previous booster immunization;
- No previous post-exposition treatment with HRIG;
- Potential deployment to rabies endemic area within study period ;
- Presence of a serious medical history with a potential effect on the immune system such
as diabetes mellitus, HIV, functional or hyposplenia/asplenia;
- Allergies to one of the components of the rabies vaccine such as chicken egg protein,
polygeline, hypersensitivity to neomycin, chlortetracycline, amphotericin B and other
antibiotics of the same class;
- Use of mefloquine or chloroquine during the study period ;
- Pregnancy ;
- Breastfeeding;
- Immune compromised due to medication such as prednisolone, TNF-alfa inhibitors,
*biologicals* or immunodeficiency due to humoral or cellular cause.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The percentage of participants with a titer of * 0.5 IU/ml at day 7<br /><br>The percentage of participants with a titer of * 0.5 IU/ml at day 14</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>The percentage of participants with a titer of * 0.5 IU/ml at day 0<br /><br>The percentage of participants with a titer of * 3.0 IU/ml at day 7<br /><br>The percentage of participants with a titer of * 3.0 IU/ml at day 14</p><br>